Mvasi (Bevacizumab)

Bevacizumab, the active ingredient in Mvasi, is a monoclonal antibody presented as an intravenous formulation for infusion use. It targets vascular endothelial growth factor‑A to inhibit tumor angiogenesis and is employed in the treatment of several advanced solid tumours.

GNH USA supplies Mvasi as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide. The company adheres to stringent quality standards and provides cold‑chain logistics for biologic products.

Mvasi is used in oncology to block VEGF‑driven angiogenesis across multiple tumour types.

- Metastatic colorectal cancer: improves progression‑free and overall survival when combined with chemotherapy. - Non‑small cell lung cancer: enhances response rates in patients receiving standard platinum‑based regimens. - Glioblastoma: prolongs survival in newly diagnosed patients when added to radiotherapy and temozolomide. - Renal cell carcinoma: delays disease progression in combination with interferon‑α or other targeted agents. - Ovarian cancer: increases progression‑free survival when combined with carboplatin‑paclitaxel therapy.

Like other anti‑angiogenic antibodies, Mvasi may be associated with a range of adverse reactions.

Common Side Effects: - Hypertension: elevated blood pressure requiring monitoring or medication. - Proteinuria: presence of protein in urine, often mild and reversible. - Fatigue: generalized tiredness that may affect daily activities. - Hemorrhage: nosebleeds or minor bleeding episodes. - Gastrointestinal perforation: rare but serious abdominal events.

Serious or Rare Side Effects: - Thromboembolic events: deep‑vein thrombosis or pulmonary embolism. - Wound healing complications: delayed or impaired postoperative healing. - Severe hemorrhage: gastrointestinal or intracranial bleeding. - Cardiac dysfunction: reduced left‑ventricular ejection fraction. - Infusion‑related reactions: anaphylaxis or severe hypersensitivity.

Prior to initiating therapy, clinicians should evaluate patient history and monitor for specific safety concerns.

- Blood pressure monitoring: control hypertension before and during treatment. - Renal function assessment: check for proteinuria and adjust therapy if significant. - Bleeding risk evaluation: avoid in patients with recent major surgery or uncontrolled coagulopathy. - Wound healing surveillance: postpone elective surgery until adequate healing has occurred. - Pregnancy and lactation: avoid use; safety data are insufficient. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the product.

Mvasi may interact with several drug classes, influencing safety or efficacy.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin, heparin): increased risk of severe bleeding. - Cytotoxic chemotherapy agents that cause mucosal damage: heightened gastrointestinal perforation risk. - High‑dose aspirin or NSAIDs: potentiates hemorrhagic complications.

Moderate Interactions (Monitor Closely): - Hypertension‑inducing agents (e.g., VEGF‑TKIs, corticosteroids): may exacerbate blood‑pressure elevations. - Immunosuppressants (e.g., cyclosporine): monitor for additive infection risk. - Radiotherapy to the abdomen or pelvis: increased chance of perforation or delayed healing.